Policy
F.D.A. Rejects Closely Watched Lung Cancer Drug From China
NYT > Health · By Rebecca Robbins ·
The Brief
- The U.S. Food and Drug Administration (FDA) has rejected ivonescimab, a lung cancer drug from China.
- The New York Times describes the drug as a closely watched symbol of China's rise in drug development.
Why it matters
The decision affects whether this Chinese-developed lung cancer treatment can be marketed in the United States, and it bears on how regulators assess drugs developed largely outside the US.
Who’s affected
- patients with lung cancer
- drug developers and regulators
- #lung cancer
- #fda
- #drug approval
- #china
- #ivonescimab
The treatment, called ivonescimab, has become a symbol of China’s rise in drug development.